PROFESSIONAL EDITION

The largest community of pharma leaders

Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

NEW YORK–(BUSINESS WIRE)–BMS & The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
Source Read More

Recent Articles